The purpose of this research study is to look at how safe and useful a drug called azacitidine in combination with a drug called venetoclax, is in people with accelerated or blast phase BRC-ABL negative myeloproliferative neoplasms.
Ability to voluntarily provide written informed consent.
Documented diagnosis per World Health Organization (WHO) 2016 criteria of BCR-ABL negative myeloproliferative neoplasms (MPN).
Documented MPN transformation to accelerated phase (AP) or blast phase (BP) without prior blast reduction therapy for their AP/BP disease.
Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
History of allogeneic stem cell transplant for MPN.
Previous treatment with venetoclax, navitoclax, azacytidine or other hypomethylating agents (HMA).
White blood cell count >25 x 10^9/L.
Current enrollment in another interventional study.
Single group
Azacitidine
DrugAzacitidine is a hypomethylating agent that works by activating certain genes in the body to help cells mature and to kill abnormal bone marrow cells.
Venetoclax
DrugVenetoclax is a drug that blocks a protein called B-cell lymphoma (BCL2) protein from working. BCL2 is a protein that helps control whether a cell lives or dies and is thought to help cancer cells to live. Blocking BCL2 is believed to help kill cancer cells.
Proportion of participants achieving complete remission (CR).
Proportion of participants achieving complete remission with incomplete hematologic recovery (CRi).
Proportion of participants achieving reversion to chronic myeloproliferative neoplasm (CMPN).
Average number of days from the first dose of azacytidine and venetoclax to the date of death.
Average number of days from CR until relapse.
Average number of days from CRi until relapse.
Average number of days from CMPN until relapse.
Click on the lead sponsor to view all of their trials.
